EBO Stock Overview
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand.
EBOS Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$38.15|
|52 Week High||NZ$43.13|
|52 Week Low||NZ$27.51|
|1 Month Change||-4.81%|
|3 Month Change||8.17%|
|1 Year Change||32.46%|
|3 Year Change||77.03%|
|5 Year Change||127.08%|
|Change since IPO||1,581.10%|
Recent News & Updates
EBOS Group Limited's (NZSE:EBO) Intrinsic Value Is Potentially 41% Above Its Share Price
Does the January share price for EBOS Group Limited ( NZSE:EBO ) reflect what it's really worth? Today, we will...
Is EBOS Group (NZSE:EBO) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
EBOS Group (NZSE:EBO) Has Some Way To Go To Become A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...
An Intrinsic Calculation For EBOS Group Limited (NZSE:EBO) Suggests It's 23% Undervalued
Does the October share price for EBOS Group Limited ( NZSE:EBO ) reflect what it's really worth? Today, we will...
|EBO||NZ Healthcare||NZ Market|
Return vs Industry: EBO exceeded the NZ Healthcare industry which returned -4.6% over the past year.
Return vs Market: EBO exceeded the NZ Market which returned -11.4% over the past year.
|EBO Average Weekly Movement||3.6%|
|Healthcare Industry Average Movement||3.5%|
|Market Average Movement||3.8%|
|10% most volatile stocks in NZ Market||6.5%|
|10% least volatile stocks in NZ Market||2.4%|
Stable Share Price: EBO is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: EBO's weekly volatility (4%) has been stable over the past year.
About the Company
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services.
EBOS Group Fundamentals Summary
|EBO fundamental statistics|
Is EBO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EBO income statement (TTM)|
|Cost of Revenue||AU$8.22b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Feb 16, 2022
|Earnings per share (EPS)||1.01|
|Net Profit Margin||2.01%|
How did EBO perform over the long term?See historical performance and comparison
2.3%Current Dividend Yield
Is EBOS Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EBO (NZ$38.15) is trading below our estimate of fair value (NZ$53.71)
Significantly Below Fair Value: EBO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EBO is poor value based on its PE Ratio (35.3x) compared to the NZ Healthcare industry average (11.3x).
PE vs Market: EBO is poor value based on its PE Ratio (35.3x) compared to the NZ market (18.8x).
Price to Earnings Growth Ratio
PEG Ratio: EBO is poor value based on its PEG Ratio (2.6x)
Price to Book Ratio
PB vs Industry: EBO is overvalued based on its PB Ratio (4.6x) compared to the NZ Healthcare industry average (1.7x).
How is EBOS Group forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EBO's forecast earnings growth (13.5% per year) is above the savings rate (2.1%).
Earnings vs Market: EBO's earnings (13.5% per year) are forecast to grow faster than the NZ market (7.3% per year).
High Growth Earnings: EBO's earnings are forecast to grow, but not significantly.
Revenue vs Market: EBO's revenue (6.5% per year) is forecast to grow faster than the NZ market (4.8% per year).
High Growth Revenue: EBO's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EBO's Return on Equity is forecast to be low in 3 years time (16.1%).
How has EBOS Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EBO has high quality earnings.
Growing Profit Margin: EBO's current net profit margins (2%) are higher than last year (1.9%).
Past Earnings Growth Analysis
Earnings Trend: EBO's earnings have grown by 8.5% per year over the past 5 years.
Accelerating Growth: EBO's earnings growth over the past year (14%) exceeds its 5-year average (8.5% per year).
Earnings vs Industry: EBO earnings growth over the past year (14%) underperformed the Healthcare industry 70.4%.
Return on Equity
High ROE: EBO's Return on Equity (13.1%) is considered low.
How is EBOS Group's financial position?
Financial Position Analysis
Short Term Liabilities: EBO's short term assets (A$2.1B) exceed its short term liabilities (A$1.9B).
Long Term Liabilities: EBO's short term assets (A$2.1B) exceed its long term liabilities (A$666.1M).
Debt to Equity History and Analysis
Debt Level: EBO's net debt to equity ratio (19.7%) is considered satisfactory.
Reducing Debt: EBO's debt to equity ratio has reduced from 34.6% to 31.7% over the past 5 years.
Debt Coverage: EBO's debt is well covered by operating cash flow (66.8%).
Interest Coverage: EBO's interest payments on its debt are well covered by EBIT (10.4x coverage).
What is EBOS Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EBO's dividend (2.31%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.76%).
High Dividend: EBO's dividend (2.31%) is low compared to the top 25% of dividend payers in the NZ market (4.97%).
Stability and Growth of Payments
Stable Dividend: EBO's dividends per share have been stable in the past 10 years.
Growing Dividend: EBO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (72.7%), EBO's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EBO's dividends in 3 years are forecast to be covered by earnings (74.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. John Cullity has been Non-Executive Director of Terry White Group Limited since March 29, 2018. Mr. Cullity has been Chief Executive Officer of EBOS Group Limited since April 1, 2018. Mr. Cullity serve...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD2.67M) is above average for companies of similar size in the NZ market ($USD1.75M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: EBO's management team is considered experienced (3.9 years average tenure).
Experienced Board: EBO's board of directors are considered experienced (8.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EBO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.3%.
EBOS Group Limited's employee growth, exchange listings and data sources
- Name: EBOS Group Limited
- Ticker: EBO
- Exchange: NZSE
- Founded: 1922
- Industry: Health Care Distributors
- Sector: Healthcare
- Implied Market Cap: NZ$7.009b
- Shares outstanding: 183.72m
- Website: https://www.ebosgroup.com
Number of Employees
- EBOS Group Limited
- 737 Bourke Street
- Level 7
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 06:01|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.